Table 3.
Analyses of Prognostic Factors for Progression-Free Survival After PSM
| Factor | Progression-Free Survival | |||
|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex (male/female) | 1.058(0.456–2.455) | 0.896 | ||
| Age (≥65/<65 years) | 0.927(0.53–1.621) | 0.791 | ||
| Child-Pugh class (A/B/C) | 0.753 | |||
| A | 1 | |||
| B | 1.056(0.256–4.358) | 0.94 | ||
| C | 1.286(0.299–5.527) | 0.736 | ||
| Number of tumors (≥2/<2) | 1.597(0.918–2.781) | 0.098 | ||
| Tumor diameter (≥5/<5 cm) | 1.784(1.027–3.097) | 0.04 | 1.062(0.55–2.051) | 0.858 |
| AFP (≥400/<400 ng/mL) | 0.818(0.51–1.31) | 0.403 | ||
| ALP (≥125/<125 U/L) | 1.739(1.073–2.819) | 0.025 | 1.202(0.705–2.049) | 0.499 |
| Platelet (<100,000/≥100,000/mL) | 1.658(0.982–2.799) | 0.059 | ||
| ALT (≥40/<40U/L) | 1.119(0.701–1.787) | 0.637 | ||
| Leukocyte (<4000/≥4000/mL) | 1.604(0.767–3.355) | 0.209 | ||
| HBV (positive/negative) | 1.264(0.738–2.165) | 0.394 | ||
| Portal vein invasion (yes/no) | 1.758(1.086–2.845) | 0.022 | 1.149(0.673–1.962) | 0.611 |
| BCLC | 0.016 | 0.204 | ||
| A | 1 | 1 | ||
| B | 0.457(0.083–2.525) | 0.369 | 0.627(0.099–3.984) | 0.621 |
| C | 0.378(0.069–2.079) | 0.264 | 0.495(0.079–3.095) | 0.452 |
| D | 1.404(0.342–5.766) | 0.638 | 1.504(0.322–7.019) | 0.604 |
| Lymph node metastasis (yes/no) | 1.302(0.816–2.077) | 0.268 | ||
| Extrahepatic metastases (yes/no) | 0.88(0.528–1.466) | 0.624 | ||
| Triple therapy (Yes/No) | 0.644(0.401–1.033) | 0.068 | ||
Abbreviations: PSM, propensity score matching; HR, hazard ratio; AFP, alpha fetoprotein; ALP, alkaline phosphatase; ALT, alanine transaminase; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer.